105 related articles for article (PubMed ID: 19043710)
21. Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing.
Mueller BU; Anderson BD; Farley MQ; Murphy R; Zuckerman J; Jarosinski P; Godwin K; McCully CL; Mitsuya H; Pizzo PA; Balis FM
Antimicrob Agents Chemother; 1998 Jul; 42(7):1815-8. PubMed ID: 9661027
[TBL] [Abstract][Full Text] [Related]
22. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.
Song P; Ma F; Wang F; Wang X; Patil R; Ramagiri S; Orr WE; Miller DD; Geisert E; Yates CR
Cancer Chemother Pharmacol; 2008 May; 61(6):1037-44. PubMed ID: 17768626
[TBL] [Abstract][Full Text] [Related]
23. Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates.
Fox E; Murphy RF; McCully CL; Adamson PC
Cancer Chemother Pharmacol; 2001; 47(1):41-4. PubMed ID: 11221960
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys.
Grygiel JJ; Balis FM; Collins JM; Lester CM; Poplack DG
Cancer Res; 1985 May; 45(5):2037-9. PubMed ID: 3986760
[TBL] [Abstract][Full Text] [Related]
25. Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates.
Cho SY; Fox E; McCully C; Bauch J; Marsh K; Balis FM
Cancer Chemother Pharmacol; 2007 Sep; 60(4):563-7. PubMed ID: 17187251
[TBL] [Abstract][Full Text] [Related]
26. Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeys.
McGovren JP; Stewart JC; Elfring GL; Smith RB; Soares N; Wood JH; Poplack DG; Von Hoff DD
Cancer Treat Rep; 1982 Jun; 66(6):1333-41. PubMed ID: 7083237
[TBL] [Abstract][Full Text] [Related]
27. Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey.
Kerr IG; Zimm S; Collins JM; O'Neill D; Poplack DG
Cancer Res; 1984 Nov; 44(11):4929-32. PubMed ID: 6488155
[TBL] [Abstract][Full Text] [Related]
28. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates.
Neville K; Parise RA; Thompson P; Aleksic A; Egorin MJ; Balis FM; McGuffey L; McCully C; Berg SL; Blaney SM
Clin Cancer Res; 2004 Apr; 10(7):2525-9. PubMed ID: 15073132
[TBL] [Abstract][Full Text] [Related]
29. Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates.
Heideman RL; Balis FM; McCully C; Poplack DG
Cancer Res; 1988 Aug; 48(15):4294-8. PubMed ID: 2455594
[TBL] [Abstract][Full Text] [Related]
30. Central nervous system distribution kinetics of indinavir in rats.
Hamidi M
J Pharm Pharmacol; 2007 Aug; 59(8):1077-85. PubMed ID: 17725849
[TBL] [Abstract][Full Text] [Related]
31. 2'-beta-fluoro-2',3'-dideoxyadenosine, lodenosine, in rhesus monkeys: plasma and cerebrospinal fluid pharmacokinetics and urinary disposition.
Roth JS; McCully CM; Balis FM; Poplack DG; Kelley JA
Drug Metab Dispos; 1999 Oct; 27(10):1128-32. PubMed ID: 10497138
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of 6-mercaptopurine (6MP) in the monkey. I. Disposition from plasma and cerebrospinal fluid following iv bolus.
Narang PK; Chatterji DC; O'Neill D; Poplack DG
Drug Metab Dispos; 1983; 11(1):5-9. PubMed ID: 6132796
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate.
Riva L; Blaney SM; Dauser R; Nuchtern JG; Durfee J; McGuffey L; Berg SL
Clin Cancer Res; 2000 Mar; 6(3):994-7. PubMed ID: 10741726
[TBL] [Abstract][Full Text] [Related]
34. Passage of MHPG from plasma to CSF in a non-human primate.
Faull KF; Pascoe N; Maddaluno J; Greene KA; Wiener SG
J Neurosci Res; 1990 Dec; 27(4):533-40. PubMed ID: 2079714
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of vincristine in the cerebrospinal fluid of subhuman primates.
Jackson DV; Castle MC; Poplack DG; Bender RA
Cancer Res; 1980 Mar; 40(3):722-4. PubMed ID: 7471091
[TBL] [Abstract][Full Text] [Related]
36. Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.
Muscal JA; Sun Y; Nuchtern JG; Dauser RC; McGuffey LH; Gibson BW; Berg SL
Cancer Chemother Pharmacol; 2012 Apr; 69(4):943-7. PubMed ID: 22109830
[TBL] [Abstract][Full Text] [Related]
37. Exploration of the African green monkey as a preclinical pharmacokinetic model: intravenous pharmacokinetic parameters.
Ward KW; Coon DJ; Magiera D; Bhadresa S; Nisbett E; Lawrence MS
Drug Metab Dispos; 2008 Apr; 36(4):715-20. PubMed ID: 18227143
[TBL] [Abstract][Full Text] [Related]
38. A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases.
Lv Y; Cheung NK; Fu BM
J Nucl Med; 2009 Aug; 50(8):1324-31. PubMed ID: 19617331
[TBL] [Abstract][Full Text] [Related]
39. Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model.
Cole DE; Lester-McCully CM; Widemann BC; Warren KE
Cancer Chemother Pharmacol; 2015 May; 75(5):923-8. PubMed ID: 25740692
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
Kurtzberg LS; Roth SD; Bagley RG; Rouleau C; Yao M; Crawford JL; Krumbholz RD; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1029-38. PubMed ID: 19277662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
